新诊断局灶性癫痫患者抗发作药物的治疗反应
人类癫痫项目是一项国际前瞻性观察性队列研究,在34个三级癫痫中心随访448例新诊断局灶性癫痫患者最长6年。结果显示59.6%达到无发作,54.7%为治疗敏感,22.8%为耐药;多数患者需超过1年和超过1种抗发作药物才实现无发作,治疗前发作频繁及精神共病与耐药相关。
要点
- 新诊断局灶性癫痫中59.6%可实现无发作,但中位首次无发作时间为12.1个月。
- 治疗敏感者占54.7%,其中89.3%对单药治疗有反应。
- 治疗前发作频繁者耐药风险更低(HR 0.30),精神共病者耐药风险升高(RR 1.78)。
核心结论
- 多数新诊断局灶性癫痫患者需超过1年和超过1种抗发作药物才能实现无发作。
- 治疗前发作频繁者可更早识别耐药,诊断时存在精神共病是重要预后因素。
研究设计与样本
- 人类癫痫项目为国际前瞻性观察性队列研究,2012至2020年在美国、澳大利亚和欧洲34个三级癫痫中心开展。
- 共纳入448例确诊局灶性癫痫、年龄12至60岁、开始抗发作药物治疗4个月内入组的患者,随访最长6年,中位随访3.13年。
主要发现
- 448例中267例(59.6%)达到无发作,其中223例(83.5%)未复发。
- 治疗敏感者245例(54.7%),耐药者102例(22.8%),不确定者101例(22.5%)。
- 治疗敏感者中217例(89.3%)对单药治疗有反应,121例(49.4%,占全队列27%)在第一种抗发作药物下即无发作。
- 治疗第一年内251例(63%)仍有发作或发作加重。
- 首次无发作中位时间为12.1个月(95%CI,9.7-16.1),从未复发者为2.2个月(95%CI,0.8-3.2),复发者为7.4个月(95%CI,4.0-10.7)。
关键数值与推荐
- 无发作定义为12个月无发作或达到治疗前最长无发作间期的3倍,取较长者。
- 治疗敏感定义为接受2种或以下足量抗发作药物试验即无发作,耐药定义为2种或以上足量药物试验失败。
- 治疗前发作不频繁者较发作非常频繁者耐药可能性更低(HR,0.30;95%CI,0.14-0.64;P=.002;Holm-Bonferroni校正P=.006)。
- 自报共病心理障碍者较无共病者耐药可能性更高(RR,1.78;95%CI,1.26-2.52;P=.001)。
临床怎么用
- 应向新诊断局灶性癫痫患者说明无发作可能需超过1年和多种药物尝试。
- 对治疗前发作频繁或合并精神共病者应更早评估耐药风险并加强随访。
局限性
- 本研究为观察性队列,抗发作药物暴露为可变因素,非随机对照设计。
- 队列来自三级癫痫中心,结果外推至一般人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Epilepsy affects approximately 65 million people worldwide, and 60% have focal seizures. Predicting seizure response and drug resistance to antiseizure medications (ASMs) in people with focal epilepsy remains difficult. OBJECTIVE: To describe the expected short- and long-term response to treatment with ASMs in people with focal epilepsy using recognized definitions by the International League Against Epilepsy. DESIGN, SETTING, AND PARTICIPANTS: The Human Epilepsy Project is an international, prospective, observational cohort study that followed up people with newly diagnosed focal epilepsy for up to 6 years between 2012 and 2020. Data were analyzed from 2023 to 2024. The Human Epilepsy Project was conducted at 34 tertiary epilepsy centers across the US, Australia, and Europe. Participants with confirmed diagnosis of focal epilepsy aged 12 to 60 years were enrolled within 4 months of treatment initiation with ASM(s). Data were analyzed from February 2024 to July 2024. EXPOSURE: ASM (variable). MAIN OUTCOMES AND MEASURES: The primary outcome was seizure freedom, defined as a period without seizures for 12 months or 3 times the longest pretreatment seizure-free interval, whichever was longer. Treatment response was categorized as sensitive, meaning seizure free receiving 2 or fewer adequate ASM trials; resistant, meaning having 2 or more adequate ASM trials fail; or indeterminate (neither treatment sensitive nor resistant). RESULTS: Among 448 enrolled participants, 267 (59.6%) were female, and median (IQR) participant age was 32 (21-44) years at treatment initiation. Median (IQR) follow-up duration was 3.13 (2.33-3.55) years. Most achieved seizure freedom (267 participants of 448 [59.6%]), largely without relapse (223 [83.5%]). There were 245 treatment-sensitive participants (54.7%), 102 treatment-resistant participants (22.8%), and 101 indeterminate participants (22.5%). Among treatment-sensitive participants, most (217 [89.3%]) responded to monotherapy and half (121 [49.4%], or 27% of total cohort) became seizure free while receiving their first ASM. In the first year of treatment, 251 participants (63%) had ongoing or worsening seizures. Median time to first seizure freedom was 12.1 months (95% CI, 9.7-16.1). This occurred earlier in those who never relapsed (median, 2.2 months; 95% CI, 0.8-3.2) than those who did (median, 7.4 months; 95% CI, 4.0-10.7). Those with infrequent pretreatment seizures were 0.30-fold less likely to be treatment resistant than those with very frequent seizures (hazard ratio, 0.30; 95% CI, 0.14-0.64; P = .002; Holm-Bonferroni-corrected P = .006). Participants with self-reported comorbid psychological disorders were 1.78-fold more likely to be treatment resistant than those without (relative risk, 1.78; 95% CI, 1.26-2.52; P = .001). CONCLUSIONS AND RELEVANCE: In the Human Epilepsy Project multicenter prospective cohort study, most people with newly diagnosed focal epilepsy took more than a year and more than 1 ASM to become seizure free. Drug resistance can be identified earlier in those with frequent pretreatment seizures, and a history of psychiatric comorbidities at epilepsy diagnosis is an important prognostic factor. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02126774.
引用
- Barnard SN, Chen Z, Holmes M, et al. Treatment Response to Antiseizure Medications in People With Newly Diagnosed Focal Epilepsy. JAMA Neurol. 2025. PMID: 40853673. doi:10.1001/jamaneurol.2025.2949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。